BACKGROUND: Significant quantities of antiretroviral drugs (ARVs) to treat HIV/AIDS have been procured for Sub-Saharan Africa for the first time in their 20-year history. This presents a novel opportunity to empirically study the roles of brand and generic suppliers in providing access to ARVs. METHODOLOGY/PRINCIPAL FINDINGS: An observational study of brand and generic supply based on a dataset of 2,162 orders of AIDS drugs for Sub-Saharan Africa reported to the Global Price Reporting Mechanism at the World Health Organization from January 2004-March 2006 was performed. Generic companies supplied 63% of the drugs studied, at prices that were on average about a third of the prices charged by brand companies. 96% of the procurement was of fir...
Affordability is a key concern of international donors who finance antiretroviral drugs to treat AID...
Statement of the issue: Facing large HIV-infected populations, Sub-Saharan African countries are pro...
AbstractBackgroundThis research focuses on pharmaceutical competition in South Africa where concurre...
Significant quantities of antiretroviral drugs (ARVs) to treat HIV/AIDS have been procured for Sub-S...
BACKGROUND Indian manufacturers of generic antiretroviral (ARV) medicines facilitated the rapid scal...
Generic and brand name antiretroviral drugs are becoming increasingly available in developing countr...
Background: Indian manufacturers of generic antiretroviral (ARV) medicines facilitated the rapid sca...
Introduction: Antiretrovirals are available at low prices in sub-Saharan Africa, but these prices ma...
Access to treatment is a key part of national strategies to combat HIV/AIDS. Antiretrovirals can inc...
As of 2011, over 34 million people lived with HIV/AIDS, and about 95 percent of this population live...
International audienceIntroduction: This study aims to provide a landscape of the global antiretrovi...
Abstract Background The price of antiretroviral drugs (ARVs) in low income countries declined steadi...
The introduction of generic antiretroviral medications in developing countries has resulted in signi...
Brazil became the first developing country to guarantee free and universal access to HIV/AIDS treatm...
Abstract High medicines prices increasingly pose challenges for universal access to treatments of co...
Affordability is a key concern of international donors who finance antiretroviral drugs to treat AID...
Statement of the issue: Facing large HIV-infected populations, Sub-Saharan African countries are pro...
AbstractBackgroundThis research focuses on pharmaceutical competition in South Africa where concurre...
Significant quantities of antiretroviral drugs (ARVs) to treat HIV/AIDS have been procured for Sub-S...
BACKGROUND Indian manufacturers of generic antiretroviral (ARV) medicines facilitated the rapid scal...
Generic and brand name antiretroviral drugs are becoming increasingly available in developing countr...
Background: Indian manufacturers of generic antiretroviral (ARV) medicines facilitated the rapid sca...
Introduction: Antiretrovirals are available at low prices in sub-Saharan Africa, but these prices ma...
Access to treatment is a key part of national strategies to combat HIV/AIDS. Antiretrovirals can inc...
As of 2011, over 34 million people lived with HIV/AIDS, and about 95 percent of this population live...
International audienceIntroduction: This study aims to provide a landscape of the global antiretrovi...
Abstract Background The price of antiretroviral drugs (ARVs) in low income countries declined steadi...
The introduction of generic antiretroviral medications in developing countries has resulted in signi...
Brazil became the first developing country to guarantee free and universal access to HIV/AIDS treatm...
Abstract High medicines prices increasingly pose challenges for universal access to treatments of co...
Affordability is a key concern of international donors who finance antiretroviral drugs to treat AID...
Statement of the issue: Facing large HIV-infected populations, Sub-Saharan African countries are pro...
AbstractBackgroundThis research focuses on pharmaceutical competition in South Africa where concurre...